Petlife Pharmaceuticals, Inc. (PTLF)

0.0001 0.0000 (0.00%) At close: 11:55AM EDT

Petlife Pharmaceuticals, Inc.

8033 Sunset Boulevard
Suite 867
Los Angeles, CA 90046
United States
424-216-6807

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sebastian Serrell-Watts	Chairman, CEO, President, CFO, Secretary & Treasurer	N/A	N/A	1965
Dr. Arthur Grant Mikaelian Ph.D.	Founder and Chief Scientific Officer	110.4k	N/A	1962

Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.

Corporate governance

Petlife Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.